Reference | Estimate [in €] | CI 95% | P-value | ||
---|---|---|---|---|---|
2.5% | 97.5% | ||||
Study group | Control group | −276.04 | − 573.18 | 21.10 | 0.0686 |
Residential area (Berlin vs. rural) | Rural | 180.81 | −49.03 | 410.65 | 0.1231 |
Interaction: Group x Residential area | 257.77 | −131.35 | 646.90 | 0.1941 | |
Age group | |||||
46–50 years | 41–45 years | 878.30 | − 652.97 | 2409.58 | 0.2609 |
51–55 years | 41–45 years | 669.75 | − 749.92 | 2089.43 | 0.3551 |
56–60 years | 41–45 years | 641.50 | −743.15 | 2026.14 | 0.3638 |
61–65 years | 41–45 years | 448.94 | − 905.54 | 1803.43 | 0.5159 |
66–70 years | 41–45 years | 828.90 | −502.34 | 2160.14 | 0.2223 |
71–75 years | 41–45 years | 1117.78 | − 210.13 | 2445.69 | 0.0990 |
76–80 years | 41–45 years | 1160.55 | − 167.31 | 2488.41 | 0.0867 |
81–85 years | 41–45 years | 973.17 | − 359.70 | 2306.04 | 0.1524 |
86–90 years | 41–45 years | 876.95 | − 471.87 | 2225.77 | 0.2025 |
91–95 years | 41–45 years | 1168.45 | − 340.20 | 2677.11 | 0.1290 |
Sex | Male | −73.85 | −245.19 | 97.49 | 0.3982 |
NYHA class | |||||
NYHA II | NYHA I | 18.38 | − 793.15 | 829.91 | 0.9646 |
NYHA III | NYHA I | 210.53 | −600.60 | 1021.65 | 0.6109 |
NYHA IV | NYHA I | 398.18 | −419.09 | 1215.45 | 0.3396 |
Hospitalizations related to CHF | (continuous) | 52.03 | −51.72 | 155.79 | 0.3256 |
Baseline health costs | (continuous) | 0.37 | 0.34 | 0.40 | < 0.0001*** |
Intake of medication related to CHF (yes / no by groups of agents) | |||||
Angiotensin-converting enzyme | no | − 139.92 | −313.52 | 33.69 | 0.1142 |
Beta-blocker | no | −279.06 | − 450.13 | − 107.98 | 0.0014** |
Renin-inhibitors | no | −75.07 | − 734.15 | 584.01 | 0.8233 |
Cardiac glycosides | no | 147.81 | −81.40 | 377.01 | 0.2062 |
Diuretics | no | 394.65 | 214.89 | 574.40 | < 0.0001*** |
AT1 receptor blocker | no | −25.55 | − 247.64 | 196.54 | 0.8216 |
Mental and behavioral disorders (yes / no by blocks of ICD-10 Chapter V) | |||||
F00 – F09 (Organic, including symptomatic, mental disorders) | no | 465.72 | 173.79 | 757.65 | 0.0018** |
F10 – F19 (Mental and behavioral disorders due to psychoactive substance use) | no | 39.64 | − 257.67 | 336.94 | 0.7938 |
F20 – F29 (Schizophrenia, schizotypal and delusional disorders) | no | −34.52 | − 936.45 | 867.41 | 0.9402 |
F30 – F39 (Mood [affective] disorders) | no | 109.85 | −120.77 | 340.48 | 0.3504 |
F40 – F49 (Neurotic, stress-related and somatoform disorders) | no | 51.25 | − 188.92 | 291.42 | 0.6757 |
F50 – F59 (Behavioral syndromes associated with physiological disturbances and physical factors) | no | 343.92 | − 130.81 | 818.64 | 0.1556 |
F60 – F69 (Disorders of adult personality and behavior) | no | −120.35 | − 859.94 | 619.25 | 0.7497 |
F70 – F79 (Mental retardation) | no | 321.91 | −921.90 | 1565.71 | 0.6119 |
F80 – F89 (Disorders of psychological development) | no | – | – | – | – |
F90 – F98 (Behavioral and emotional disorders with onset usually occurring in childhood and adolescence) | no | 612.00 | − 991.08 | 2215.09 | 0.4542 |
F99 – F99 (Unspecified mental disorders) | no | 490.90 | − 1333.73 | 2315.52 | 0.5979 |
Intercept | – | 249.86 | − 1318.15 | 1817.88 | 0.7548 |